Cancer's next decade
After a decade of patient breakthroughs leveraging technologies like immunotherapy, ADCs and targeted therapies, cancer R&D is staring down its next era. Our expert panel will look at how the R&D landscape has shifted, new attempts to go after cancer's “undruggable” targets and how the field is thinking about where the goalposts are in what remains a crowded space.
![Charles Fuchs](./assets/img/panelists/CharlesFuchs.jpg)
Charles Fuchs
Senior Vice President - Global Head of Oncology and Hematology Product Development
Genentech and Roche
![Christiana Bardon](./assets/img/panelists/ChristianaBardon.jpg)
Christiana Bardon
Co-Managing Partner
MPM BioImpact
![Steve Wedge](./assets/img/panelists/SteveWedge.jpg)
Steve Wedge
Chief Scientific Officer, Therapeutic Innovation
Cancer Research Horizons
![Amber Tong](./assets/img/panelists/AmberTong.jpg)
Amber Tong
Senior Editor